Disclosure: I am here for the Patents plural and

New Post Public Reply Private Reply Replies (0) Message Board

Mar 22, 2013 at 9:37 PM

Disclosure: I am here for the Patents plural and intellectual property rights related to Eli 216 and 154 and the real money garnered in relation to them. Still 2-4 years away IMO but quickly becoming much more of a reality as opposed to my first purchased shares in 2011. It has been more than a painful ride. In my further opinion, there has been no better time than these past few months to purchase shares in relation to what the company is doing related to their pipeline. Elite has the technology to more than challenge Purdue and Pfizer in the Abuse Resistant Opioid space.

There used to be 6 Abuse Resistant Products on the market.....NOW there are only 5 as Pfizer has been unable to rectify Embedas stability issues.

1) Suboxone
2) Oxycontin
3) Opana
4) Oxecta
5) Exalgo

6) Embeda (Whoops)

Now out of those 5 Abuse Resistant Opioids on the market...........Actavis has rights to the generic version of every single one of those above products EXCEPT Embeda.....and if you know anything about the history between Pfizer and Actavis related to Embeda....you realize the only place Actavis is going to get the rights to its own version of Embeda is for Elite to build Actavis a better Embeda.....which it is doing IMO via Mik001. The other possibility I see is a Hydromorphone/Naltrexone product....but I hope for Elite's sake Mik001 is a Better Embeda and not a Hydro /Nal product. My conclusion related to the latter will become clear below.

Once you begin to understand the magnitude of a company like Actavis needing to come to Elite to get in on a product that it cannot make itself you begin to get even an inkling of the Abuse Resistant technology (ART) that Elite owns itself outright. And note that Actavis came to Elite for Embeda before Elite garnered the patents on the very technology that Elite is using to make that better Embeda.

Now it is true that Elite had best keep moving forward on their Abuse Resistant Drugs! Should the FDA and/or Congress mandate new opioid formulations to carry abuse deterrent properties the already competitive Abuse REsistant space will do nothing but heat up and heat up quickly for that matter IMO. Still, Elite will be sitting pretty in one of only a few catbird seats regarding many generic companies needing to license abuse deterrent technology as they won't have the time or money to create their own technologies and yet these companies will still wish to compete in the multi billion dollar abuse deterrent opioid space. They will only have so many choices in regards to licensing this abuse deterrent technology from pharmaceutical companies that already own their own abuse deterrent technology such as Elite owns.

Then you take what JT has already publicly mentioned regarding his personal goal......to put out a whole line of Abuse Resistant Opioids with their patented technology. One possibility would be to put out a Branded Abuse Resistant product such as Embeda but say with Hydromorphone/Naltrexone. As far as I can tell there isn't a product of this combination on the market currently.

How would a company like Actavis then obtain the generic rights to this Branded Hydromorphone/Naltrexone product as the company plans to own the generic rights to as many abuse resistant opioids as it can obviously ???

If the FDA moves in the fashion it looks like it will be heading.....Actavis would only be able to submit little of Elite's data as the reference listed drug to Actavis's Hydro/Nal Anda submission.....bc Elite will have used Patented technology for this NDA drug. Even if Elite wanted to let Actavis use their reference listed drug data.....the FDA wouldn't let Actavis as Actavis would need to license Elite's technology or come up with their own Abuse Deterrent technology and then see what the FDA would say about doing so?? What the FDA would do in the latter scenario is yet unknown but has significant positive financial bearing on Elite no matter how the FDA decides down the road on the matter IMO.

I realize Elite has the capability of making their Eli 216 product itself....within that Billion Dollar space......that is a Game Changer in and of itself for Elite.....but when you consider Elite's Intellectual Property rights potential for their patented Abuse REsistant technology (ART) and the possibilities become absolutely staggering! This staggering possibility is when you begin to realize that shares bought now have the real potential to set one up for a really nice retirement.

***** These are solely my opinions and have come to me over considerable time through my own hard fought due diligence on the company....do not buy shares on my opinions. Do your own DD and make up your own mind related to ELTP. Good luck to you and if you have questions ask. I am happy to say this board has many savvy traders and investors well beyond my years.

Elite Pharmaceuticals Inc (ELTP) Stock Research Links

ELTP Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Buy-Side Index Reveals State Market Variance

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

Americas Cardroom's Poker Series Hits $7.2M Haul

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Streamlined AI Video Analytics for Public Safety Unveiled

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Jari Spirits Set to Shake Up U.S. Market After Big Wins

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Supply Maverick Simplifies Global Shipping Processes

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...